We are requesting a 5-year competing renewal of our NIDA P30 Center with support for the 6 current Cores (Administrative, Animal, Biochemical Pharmacology, Cell and Immunology, Integrative Pharmacology, and Molecular Biology) and the addition of a seventh, the Database and Drug Interactions Core. Since its inception, the P30 Center has enhanced productivity, synergy, and multidisciplinary research, and enabled the recruitment of new faculty into the field of drugs of abuse. Major integrative themes of our Center include 1) Neuroimmunopharmacology including the study of the effects of drugs of abuse on HIV, 2) Study of drugs of abuse, particularly opioids and cannabinoids, in regulation of inflammation, pain, body temperature, reinforcement, and immune function, and 3) Drug interaction studies which are vital because individuals rarely abuse a single drug. New directions include increased emphasis on cannabinoids and additional studies on the relationship between drugs of abuse and HIV. The scope of the ongoing and future projects in the Center marries in vivo and in vitro approaches that examine effects of drugs at the cellular, biochemical, molecular and whole-organism levels. Integration of information ranging from measurements of behavior to gene activation has stimulated collaborations leading to novel hypotheses and results. The Cores of the P30 Center have fostered multidisciplinary interactions resulting in a true intellectual integration and synergy leading to hypothesis building and implementation of lines of experimentation not previously conceived. The results from the collaborative studies supported by the P30 Cores have been truly innovative. The Center also is a focus for training students, postdoctoral fellows, and junior faculty. Temple University has made major commitments to the Center that will sustain growth in the area of drug abuse research in the future. The Center is the glue that brings together investigators currently funded by NIH or other Federal or non-Federal sources and enhances and extends the effectiveness of research related to drug abuse and addiction in a cost-efficient manner. Cutting edge research being conducted by members of CSAR is supported and enhanced by utilizing the expertise, methodologies, and techniques provided by the Cores.

Public Health Relevance

Drug abuse and addiction continue to be a major public problem with enormous personnel, societal and public health costs. The goal of the P30 Center is to provide cutting-edge resources for investigators to study the impact of drugs of abuse on physiological and pathological processes. The core facilities will enhance and expand the scope of research on drugs of abuse, thus facilitating important scientific discoveries with the overall aim of reducing drug abuse and formulating new important therapeutics.

Agency
National Institute of Health (NIH)
Institute
National Institute on Drug Abuse (NIDA)
Type
Center Core Grants (P30)
Project #
5P30DA013429-15
Application #
8676753
Study Section
Special Emphasis Panel (ZDA1-EXL-T (02))
Program Officer
Purohit, Vishnudutt
Project Start
2000-09-30
Project End
2015-04-30
Budget Start
2014-05-01
Budget End
2015-04-30
Support Year
15
Fiscal Year
2014
Total Cost
$1,228,730
Indirect Cost
$409,577
Name
Temple University
Department
Pharmacology
Type
Schools of Medicine
DUNS #
057123192
City
Philadelphia
State
PA
Country
United States
Zip Code
19122
Console-Bram, Linda; Brailoiu, Eugen; Brailoiu, Gabriela Cristina et al. (2014) Activation of GPR18 by cannabinoid compounds: a tale of biased agonism. Br J Pharmacol 171:3908-17
Miller, Jonathan S; Barr, Jeffrey L; Harper, Lauren J et al. (2014) The GSK3 signaling pathway is activated by cocaine and is critical for cocaine conditioned reward in mice. PLoS One 9:e88026
Zhao, Pingwei; Lane, Tom R; Gao, Helen G L et al. (2014) Crucial positively charged residues for ligand activation of the GPR35 receptor. J Biol Chem 289:3625-38
Chatila, W M; Criner, G J; Hancock, W W et al. (2014) Blunted expression of miR-199a-5p in regulatory T cells of patients with chronic obstructive pulmonary disease compared to unaffected smokers. Clin Exp Immunol 177:341-52
Enman, Nicole M; Zhang, Yong; Unterwald, Ellen M (2014) Connecting the pathology of posttraumatic stress and substance use disorders: monoamines and neuropeptides. Pharmacol Biochem Behav 117:61-9
Shi, Xiangdang; Miller, Jonathan S; Harper, Lauren J et al. (2014) Reactivation of cocaine reward memory engages the Akt/GSK3/mTOR signaling pathway and can be disrupted by GSK3 inhibition. Psychopharmacology (Berl) 231:3109-18
Kong, Weimin; Li, Hongbo; Tuma, Ronald F et al. (2014) Selective CB2 receptor activation ameliorates EAE by reducing Th17 differentiation and immune cell accumulation in the CNS. Cell Immunol 287:1-17
Dimattio, K M; Yakovleva, T V; Aldrich, J V et al. (2014) Zyklophin, a short-acting kappa opioid antagonist, induces scratching in mice. Neurosci Lett 563:155-9
Lucchesi, Valentina; Hurst, Dow P; Shore, Derek M et al. (2014) CB2-selective cannabinoid receptor ligands: synthesis, pharmacological evaluation, and molecular modeling investigation of 1,8-Naphthyridin-2(1H)-one-3-carboxamides. J Med Chem 57:8777-91
Cathel, Alessandra M; Reyes, Beverly A S; Wang, Qin et al. (2014) Cannabinoid modulation of alpha2 adrenergic receptor function in rodent medial prefrontal cortex. Eur J Neurosci 40:3202-14

Showing the most recent 10 out of 195 publications